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Glycemic Variability: Can We Bridge the
Divide Between Controversies?
W
hat does it take to put glucose
variability into or out the heart of
glycemic disorders in type 2 di-
abetes? By analyzing the database of the
Hyperglycemia and Its Effect After Acute
Myocardial Infarction on Cardiovascular
Outcomes in Patients With Type 2 Di-
abetes Mellitus) HEART2D trial, a pre-
monitory acronym, Siegelaar et al. (1)
have reported in this issue of Diabetes
Care that glycemic variability cannot be
placed at the heart of the risk factors im-
plicated in the progression of cardio-
vascular diseases in people with type 2
diabetes. The HEART2D trial (2) was
initially designed to know whether con-
trol of basal hyperglycemia or postpran-
dial hyperglycemia is best for reducing
cardiovascular outcomes in patients with
type2 diabetes who had ahistory of myo-
cardial infarction. In order to answer
this question, the investigators of the
HEART2D trial have enrolled poorly con-
trolled type 2 diabetic patients who had
experienced acute myocardial infarction.
Patients were further assigned to either a
basal insulin strategy that targeted fasting
and interprandial glycemia or an insulin
regimen with three daily injections of a
rapid insulin analog at premeal times in
order to target postprandial glucose ex-
cursions. A similar lowering effect on am-
bient (sustained chronic) hyperglycemia
assessed by HbA1c levels was observed
with the two insulin regimens. No differ-
ence in the incidence of cardiovascular
events was detected between the two reg-
imensdespitethattheprandialgrouphad
lower postprandial glycemia compared
with the basal group at interim analysis,
when the study was halted after a mean
follow-up of 2.7 years. Even though the
authorsoftheHEART2Dtrialdidnotper-
form any speciﬁc assessment of glycemic
variability, a rapid glance at the 7-point
glycemicproﬁleseemstoindicatethatthe
range of glycemic variability was different
between the prandial and basal insulin
regimens at study end. The analysis by
Siegelaar et al. (1) was designed for quan-
tifying these differences. Unfortunately,
the results indicate that glycemic variabil-
ity did not differ between the two groups
when classical well-recognized markers
of within-day glycemic variability—SD
around the mean glucose value and the
mean amplitude of glycemic excursions
(MAGE) (3)—were used. Signiﬁcant dif-
ferenceswereonlyobserved when usinga
new marker, the mean absolute glucose
(MAG) change, which calculates the
slopes of the absolute increments and
decrements from peaks to nadirs (1).
However, it should be noted that this
marker, which includes time as x-axis co-
ordinate, is more a reﬂection of the kinet-
ics of glycemic changes per unit of time
than a true assessment of the magnitude
of absolute glucose ﬂuctuations. In addi-
tion, it should be noted that this marker
was never validated elsewhere.Therefore,
before detailing the pros and cons argu-
ments for the possible impact of glycemic
variability on the development or pro-
gression of micro- or macrovascular com-
plications in type 2 diabetes, we are left
with a mixed impression that the analysis
by Siegelaar et al. (1) is not appropriately
designedfor drawingany ﬁrm conclusion
and for permitting to gain further insight
intothedebatewhetherglycemicvariabil-
ity is an important risk factor of diabetes
c o m p l i c a t i o n s .T h e r e f o r e ,s u c hr e s u l t s
should be discussed and integrated in a
broader context.
Consider that glycemic disorders can
be separated into two independent com-
ponents: the sustained chronic or ambient
hyperglycemia and the glycemic variabil-
ity characterized by acute glucose swings
from peaks to nadirs. At present, there is
cogent evidence for the deleterious effect
oftheformerglycemicdisorder(4–6).Asa
consequence, the pathogenesisof vascular
complications in type 2 diabetes can be
depicted by a very simple “catenary
model,” in which cardiovascular out-
comes result from an excess of glycation
caused by a sustained glucose exposure
thatinturncanbeassessed andquantiﬁed
by using quarterly determinations of
HbA1c levels (7,8). Ambient glucose ex-
posure results not only from basal hy-
perglycemia but also from postprandial
hyperglycemia. The latter parameter can
participate in the development of diabetes
complications at least because its absolute
impact on HbA1c, expressed as percentage
points of HbA1c, is constant at approxi-
mately 1% across the HbA1c continuum
in non–insulin-treated diabetic patients
who have an HbA1c level .6.5% (9,10).
Postprandial glucose excursions can exert
deleterious pathophysiological effects
through other mechanisms. For instance,
besides their role in glycation, postpran-
dial glucose excursions can be a cause for
vascular diseases through the activation of
oxidative stress (11). More generally, in
people with type 2 diabetes, it has been
demonstrated that the oxidative stress is
activated by acute glucose ﬂuctuations
(12,13). According to these observations,
thepathophysiologyofdiabetescomplica-
tions can be extended from a simple cate-
nary model to a “parallel catenary model,”
inwhichthetwoparallelarmscorrespond
to the sustained chronic hyperglycemia
and the glycemic variability with their
two subsequent consequences: the excess
ofglycationandtheactivationofoxidative
stress, respectively. Unfortunately, the
data of the HEART2D trial (1,2) do not
seem to support such a model since the
apparent improvement in glycemic vari-
ability as observed in the prandial group
has no signiﬁcant impact on the progres-
sion of macrovascular complications.
These results are in agreement with those
reported in two retrospective analyses of
the Diabetes Control and Complications
Trial (DCCT) datasets (14,15). These re-
ports concluded that glucose variability
has only a minor contribution to micro-
vascular complications of type 1 diabetes.
The data obtained by the HEART2D trial
investigators extend this concept to mac-
rovascular complications of type 2 diabe-
tes treated with insulin. Such results raise
new questions. A few years ago, we have
shown that glycemic variability exerts a
strong trigger effect on oxidative stress in
type 2 diabetic patients who were treated
with oral hypoglycemic agents alone (12).
In addition, several studies seem to indi-
cate that activation of oxidative stress is
probablyoneofthekeyfactorsinthepath-
ogenesis of diabetes complications (6). As
the results of the HEART2D trial suggest
that glucose variability is not a risk factor
forcardiovasculardiseasesinpatientswith
type 2 diabetes treated with insulin (1,2),
several “burning” questions can be raised,
whycould glucose variability be arisk fac-
tor for cardiovascular diseases in patients
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oralhypoglycemicagentsalone,butnotin
those who are treated with insulin, and
does insulin per se neutralize the deleteri-
ous effects of glycemic variability on oxi-
dative stress in patients treated with it?
A piece of evidence in favor of the
latter hypothesis was provided by the
results that we have recently reported in
Diabetologia( 1 6 ) .I nac r o s s - s e c t i o n a l
study that compared three groups of pa-
tientswithtype1diabetesandwithtype2
diabetes treated either with oral hypogly-
cemic agents alone or in combination
with insulin, we demonstrated that insu-
lin therapy per se exerts an independent
inhibitory effectonactivationofoxidative
stress.Inasettingof induced endotoxine-
mia, Dandona et al. (17) have conﬁrmed
these results. From a pathophysiological
point of view, these observations seem to
provideaunifyingexplanationforthedis-
crepancies that have been previously re-
ported between insulin-treated type 1 (18)
and non–insulin-treated type 2 diabetes
(12) in terms of oxidative stress. In addi-
tion, the inhibitory effect of insulin could
help to explain why smaller glucose ﬂuc-
tuations with prandial insulin regimens in
the HEART2D trial did not improve car-
diovascular outcomes compared with
basal insulin regimens (1,2). These con-
siderations and observations lead to the
suggestion that glucose variability does
not contribute signiﬁcantly to vascular
complications of patients with type 2 di-
abetes as soon as they are treated with in-
sulin. Therefore the negative results of the
HEART2D trial demand special atten-
tion, and the lessons from this study
are probably more important than the
conclusions that were initially drawn.
This type of situation evokes the famous
Sherlock Holmes’ remark to his assis-
tant, Doctor Watson, that in a certain
case it was the dog’s behavior that had
attracted his attention. When Watson
replied that the dog had done nothing,
Sherlock Holmes explained that that, in
fact, was the important clue. This lesson
can be relevant to many clinical studies
such as the HEART2D trial.
Returning to the initial question, what
doesittaketoputglucosevariabilityintoor
out of the heart of glycemic disorders in
type 2 diabetes? there is “consensus” that
total glucose exposure as reﬂected by
HbA1c levels represents a major risk factor
for the development or progression of di-
abetes complications. However, there is
continuing dissent (“dissensus”)o ng l y c e -
mic variability. At present, there is no
evidence-based data that permit to have a
clear opinion on its exact role, but despite
inconsistencies across the resultsofthedif-
ferentstudies,the“nonsensus”wouldbeto
systematically exclude the glycemic vari-
ability from the list of potential risk factors
for diabetes complications. In conclusion,
further studies are warranted for conﬁrm-
ingorrefutingtheroleofglycemicvariabil-
ity.Forthemoment,wearenotcertainlyat
the end of the glucose variability story, but
itis difﬁcultto know whether we are at the
beginning of the end or at the end of the
beginning (19–21).
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